Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001517022-25-000024
Filing Date
2025-04-29
Accepted
2025-04-29 16:06:53
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A defacoverpage1.htm DEFA14A 8584
2 EX-99 akebiatherapeuticsinc_vx.htm EX-99 4047
3 akebiatherapeuticsinc_vx001.jpg GRAPHIC 164878
4 akebiatherapeuticsinc_vx002.jpg GRAPHIC 135058
  Complete submission text file 0001517022-25-000024.txt   426897
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36352 | Film No.: 25887211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)